Search PubMed⌕ Search

Biomedical subjects

R L Simpson

Publications and source records attributed to R L Simpson.

At least 109 records · Page 6Linked to original sources
PubMed1996

Protecting nursing's interests: negotiating with vendors.

When making technology system selections or upgrades, nurse executives are expected to negotiate with vendors as well as the CIO and department directors. Guidelines to use at the bargaining table are given.

Hospital Information Systems↗
PubMed1996

Agreement on nursing terminology: the key to technology-based outcomes management.

Automated technology is critical to the efficient and effective documentation and aggregation of outcomes data. Although the technology exists to accomplish this, it is impeded by the lack of agreement within the nursing community about outcomes-related terminology. To be measured, outcomes must be codified, referring to consistent expression and definition of outcomes. This goal has not yet been reached in nursing. Minimum data sets have been established for nursing, and work is under way to develop the related terms. The development of terms will be accelerated by mapping, in which like terms are grouped (or mapped) together to indicate the same meaning.

Databases, Factual↗
PubMed1996

What we have here is a failure to communicate....

Implementing large-scale information system (IS) projects can be challenging; projects can get bogged down with technical and logistical details. Yet, the biggest threat is a communication style that does not meet the needs of the team involved.

Communication↗
PubMed1996

Wireless communications: a new frontier in technology.

Within the last 5 to 10 years, health care has seen a plethora of "breakthrough" technologies--client/server computing, multitasking, multi-user operating systems, E-mail, CD-ROM data storage, the Internet, etc. Now, a newer technology is coming of age. This point-of-care technology uses radio-based systems to transmit signals through the air without physical connections.

Humans↗
PubMed1995

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.

The major antihypertensive effect of losartan, a nonpeptide angiotensin II antagonist, is thought to be due to inhibition of the pressor effects of angiotensin II. It is possible, however, that losartan alters the synthesis of vasodilator or vasoconstrictor prostaglandins (PG), thus contributing to its antihypertensive effect. Sixteen postmenopausal women with essential hypertension, with a mean age of 59 years and diastolic blood pressures of 95 to 115 mm Hg, were enrolled in a 12-week, single-blind study to determine the effects of losartan on blood pressure, renal and extrarenal PG production, plasma renin activity (PRA), plasma aldosterone, and routine biochemical parameters. The subjects received placebo during weeks 1 to 4, 50 mg losartan daily during weeks 5 to 8, and placebo during weeks 9 to 12. During the 4-week treatment period, there were no significant, sustained changes in renal or extrarenal synthesis of PGE2, PGI2, or thromboxane A2. Losartan significantly reduced systolic blood pressure from 155 +/- 11 mm Hg (mean +/- SD) to 139 +/- 13 mm Hg (P = .001) and diastolic blood pressure from 100 +/- 2 mm Hg to 87 +/- 5 mm Hg (P < .001) despite the fact that the majority of patients had low PRA. Plasma aldosterone concentration decreased from 9.7 +/- 6.5 ng/dL to 5.1 +/- 3.9 ng/dL (P = .002) and serum uric acid declined from 4.6 +/- 0.8 mg/dL to 4.2 +/- 0.8 mg/dL (P = .018) after 4 weeks of treatment with losartan. We conclude that 1) losartan decreases blood pressure in women with essential hypertension and low plasma renin activity; 2) the antihypertensive effect is not associated with sustained changes in renal or extrarenal PG production; and 3) losartan reduces plasma aldosterone and serum uric acid concentrations in patients with essential hypertension.

Aged↗